Skip to main content
. 2020 Oct 9;184(5):857–870. doi: 10.1111/bjd.19460

Figure 2.

Figure 2

(a) Mean log‐scaled concentrations of dupilumab in serum vs. nominal time: concentration–time profile of the phase IIa study. (b) Mean log‐scaled concentrations of dupilumab in serum vs. nominal time: concentration–time profile of the phase III open‐label extension (OLE) study.

Horizontal arrows show timepoints of dupilumab administration. For both panels, concentrations below the limit of quantitation were set as LLOQ/2. LLOQ, lower limit of quantitation.